About Protein Njmu-R1
Protein Njmu-R1 (C17orf75) is a protein
from Homo sapiens identified by UniProt accession
Q9HAS0, 396 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Protein Njmu-R1 |
|---|
| UniProt accession | Q9HAS0 |
|---|
| Gene | C17orf75 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 396 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.26
- systolic blood pressure · score 0.22
- substance abuse · score 0.18
- attention deficit hyperactivity disorder · score 0.18
- antisocial behaviour measurement · score 0.18
- schizophrenia · score 0.15
- smoking status measurement · score 0.13
- colorectal cancer · score 0.01
- neoplasm · score 0.00
- hepatocellular carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9HAS0-F1 | alphafold | PREDICTED | 76.66 | — |
Amino-acid sequence (396 residues)
MLPSLQESMD GDEKELESSE EGGSAEERRL EPPSSSHYCL YSYRGSRLAQ QRGDSEDGSP SGTNAETPSG DDFSLSLADT NLPSEVEPEL RSFIAKRLSR GAVFEGLGNV ASVELKIPGY RVGCYYCLFQ NEKLLPETVT IDSERNPSEY VVCFLGGSEK GLELFRLELD KYIQGLKNNM NCEARGLESH IKSYLSSWFE DVVCPIQRVV LLFQEKLTFL LHAALSYTPV EVKESDEKTK RDINRFLSVA SLQGLIHEGT MTSLCMAMTE EQHKSVVIDC SSSQPQFCNA GSNRFCEDWM QAFLNGAKGG NPFLFRQVLE NFKLKAIQDT NNLKRFIRQA EMNHYALFKC YMFLKNCGSG DILLKIVKVE HEEMPEAKNV IAVLEEFMKE ALDQSF
Explore Protein Njmu-R1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets